# IRX-2, Cyclophosphamide, and Nivolumab in Treating Patients With Recurrent or Metastatic and Refractory Liver Cancer

> **NCT03655002** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **City of Hope Medical Center** · enrollment: 8 (actual)

## Conditions studied

- Recurrent Hepatocellular Carcinoma
- Refractory Liver Carcinoma
- Stage IV Hepatocellular Carcinoma AJCC v8
- Stage IVA Hepatocellular Carcinoma AJCC v8
- Stage IVB Hepatocellular Carcinoma AJCC v8

## Interventions

- **DRUG:** Cyclophosphamide
- **BIOLOGICAL:** Cytokine-based Biologic Agent IRX-2
- **BIOLOGICAL:** Nivolumab

## Key facts

- **NCT ID:** NCT03655002
- **Lead sponsor:** City of Hope Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2019-02-21
- **Primary completion:** 2027-03-02
- **Final completion:** 2027-03-02
- **Target enrollment:** 8 (ACTUAL)
- **Last updated:** 2026-04-20

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03655002

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03655002, "IRX-2, Cyclophosphamide, and Nivolumab in Treating Patients With Recurrent or Metastatic and Refractory Liver Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03655002. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*